Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccine Processing Materials From BSE Countries To Be Removed By 2001

Executive Summary

Bovine-derived materials used in vaccine manufacturing will be sourced only from countries determined to be free of bovine spongiform encephalopathy within the next year, FDA Office of Vaccines Research & Review Acting Director William Egan, PhD, said July 27.

You may also be interested in...



FDA’s 2002 Regulatory Agenda, In Brief

IRB registration: FDA to propose rule requiring institutional review boards to register with the agency. Registration information would include name of institution operating the IRB, detailed contact information for "the senior officer of the institution and IRB chair or contact, the range of active protocols...involving FDA-regulated products reviewed in previous calendar year, and a description of the types of...products reviewed." The rule is intended to "make it easier for FDA to inspect IRBs and to convey information to IRBs," HHS' Unified Agenda for 2002 explains. FDA is also endorsing a voluntary IRB accreditation system...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel